Anbio Biotechnology
NNNN- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001982708
No open-market purchases or sales by Anbio Biotechnology insiders were filed in the last 90 days; 12 institutions reported holding it in 13F filings for Q2 2026, worth $985.2K in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +4 vs. previous quarter
- 12
- 13F valueReported value at the end of Q2 2026
- $985.2K
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding NNNN, Q2 2026
No superinvestor reported holding NNNN at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Anbio Biotechnology insiders from Form 4, newest first.
No open-market purchases or sales by Anbio Biotechnology insiders are on file.
Top 10 13F holders, Q2 2026
The largest institutional positions in Anbio Biotechnology at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Geode Capital Management, LLC | 26,736 | $366.6K | 0.00% | +973+3.8% | Added |
| Bank of America Corp | 13,419 | $184.0K | 0.00% | +13,419 | New |
| BNP Paribas Arbitrage, SA | 11,800 | $161.8K | 0.00% | +1,400+13.5% | Added |
| Marshall Wace, LLP | 11,502 | $157.7K | 0.00% | +11,502 | New |
| Morgan Stanley | 7,231 | $99.1K | 0.00% | −107−1.5% | Reduced |
| UBS Group AG | 828 | $11.4K | 0.00% | −5,511−86.9% | Reduced |
| EverSource Wealth Advisors, LLC | 187 | $2.56K | 0.00% | −79−29.7% | Reduced |
| Advisor Group Holdings, Inc. | 77 | $1.06K | 0.00% | +77 | New |
| JPMorgan Chase & Co | 53 | $718 | 0.00% | +53 | New |
| Bare Financial Services, Inc | 15 | $206 | 0.00% | 00.0% | Unchanged |